JP2006524038A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006524038A5 JP2006524038A5 JP2006500788A JP2006500788A JP2006524038A5 JP 2006524038 A5 JP2006524038 A5 JP 2006524038A5 JP 2006500788 A JP2006500788 A JP 2006500788A JP 2006500788 A JP2006500788 A JP 2006500788A JP 2006524038 A5 JP2006524038 A5 JP 2006524038A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- pharmaceutical composition
- acid sequence
- androgen
- signaling pathway
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003098 androgen Substances 0.000 claims description 17
- 102000004169 proteins and genes Human genes 0.000 claims description 16
- 108090000623 proteins and genes Proteins 0.000 claims description 16
- 108010066551 Cholestenone 5 alpha-Reductase Proteins 0.000 claims description 11
- 201000004384 Alopecia Diseases 0.000 claims description 7
- 108010044467 Isoenzymes Proteins 0.000 claims description 6
- 208000024963 hair loss Diseases 0.000 claims description 6
- 230000003676 hair loss Effects 0.000 claims description 6
- 238000011282 treatment Methods 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 3
- 230000003779 hair growth Effects 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims description 3
- 229940124597 therapeutic agent Drugs 0.000 claims description 3
- AKHONHCNYRUTLT-NXBFSHDWSA-N (8R,9S,10R,13S,14S,17S)-15,15,17-trihydroxy-10,13-dimethyl-2,6,7,8,9,11,12,14,16,17-decahydro-1H-cyclopenta[a]phenanthren-3-one Chemical group O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4(O)O)O)[C@@H]4[C@@H]3CCC2=C1 AKHONHCNYRUTLT-NXBFSHDWSA-N 0.000 claims description 2
- 239000000651 prodrug Substances 0.000 claims description 2
- 229940002612 prodrug Drugs 0.000 claims description 2
- 210000004761 scalp Anatomy 0.000 claims description 2
- 150000007523 nucleic acids Chemical group 0.000 claims 20
- 239000008194 pharmaceutical composition Substances 0.000 claims 15
- 230000019491 signal transduction Effects 0.000 claims 14
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 13
- 229920002477 rna polymer Polymers 0.000 claims 11
- 230000002401 inhibitory effect Effects 0.000 claims 7
- 108020004707 nucleic acids Proteins 0.000 claims 7
- 102000039446 nucleic acids Human genes 0.000 claims 7
- 210000004027 cell Anatomy 0.000 claims 5
- 108020004999 messenger RNA Proteins 0.000 claims 5
- 102000009878 3-Hydroxysteroid Dehydrogenases Human genes 0.000 claims 4
- 101710172561 3alpha-hydroxysteroid dehydrogenase Proteins 0.000 claims 4
- 102100029361 Aromatase Human genes 0.000 claims 4
- 108010078554 Aromatase Proteins 0.000 claims 4
- 102100036504 Dehydrogenase/reductase SDR family member 9 Human genes 0.000 claims 4
- 102000004316 Oxidoreductases Human genes 0.000 claims 4
- 108090000854 Oxidoreductases Proteins 0.000 claims 4
- 101000744001 Ruminococcus gnavus (strain ATCC 29149 / VPI C7-9) 3beta-hydroxysteroid dehydrogenase Proteins 0.000 claims 4
- 108010087999 Steryl-Sulfatase Proteins 0.000 claims 4
- 102100038021 Steryl-sulfatase Human genes 0.000 claims 4
- 102000001307 androgen receptors Human genes 0.000 claims 4
- 108010080146 androgen receptors Proteins 0.000 claims 4
- 230000003834 intracellular effect Effects 0.000 claims 2
- 150000003515 testosterones Chemical class 0.000 claims 2
- YBIYFJLLJFMDFQ-UHFFFAOYSA-N 4-piperidin-1-ylpyrimidine Chemical compound C1CCCCN1C1=CC=NC=N1 YBIYFJLLJFMDFQ-UHFFFAOYSA-N 0.000 claims 1
- 210000002768 hair cell Anatomy 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 230000001737 promoting effect Effects 0.000 claims 1
- 102000034285 signal transducing proteins Human genes 0.000 claims 1
- 108091006024 signal transducing proteins Proteins 0.000 claims 1
- 239000000203 mixture Substances 0.000 description 8
- ZFMITUMMTDLWHR-UHFFFAOYSA-N Minoxidil Chemical compound NC1=[N+]([O-])C(N)=CC(N2CCCCC2)=N1 ZFMITUMMTDLWHR-UHFFFAOYSA-N 0.000 description 7
- 229960003632 minoxidil Drugs 0.000 description 7
- DBEPLOCGEIEOCV-WSBQPABSSA-N finasteride Chemical compound N([C@@H]1CC2)C(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)NC(C)(C)C)[C@@]2(C)CC1 DBEPLOCGEIEOCV-WSBQPABSSA-N 0.000 description 6
- 229960004039 finasteride Drugs 0.000 description 5
- 239000002677 5-alpha reductase inhibitor Substances 0.000 description 4
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- -1 X-301 Chemical compound 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 102100033875 3-oxo-5-alpha-steroid 4-dehydrogenase 2 Human genes 0.000 description 2
- 229940113178 5 Alpha reductase inhibitor Drugs 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 101000640851 Homo sapiens 3-oxo-5-alpha-steroid 4-dehydrogenase 2 Proteins 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 229910021645 metal ion Inorganic materials 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- BDJRBEYXGGNYIS-UHFFFAOYSA-N nonanedioic acid Chemical compound OC(=O)CCCCCCCC(O)=O BDJRBEYXGGNYIS-UHFFFAOYSA-N 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 229960003604 testosterone Drugs 0.000 description 2
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- ZIMGGGWCDYVHOY-UHFFFAOYSA-N 3-hydroxy-2-imino-6-(1-piperidinyl)-4-pyrimidinamine Chemical compound N=C1N(O)C(N)=CC(N2CCCCC2)=N1 ZIMGGGWCDYVHOY-UHFFFAOYSA-N 0.000 description 1
- 108010029908 3-oxo-5-alpha-steroid 4-dehydrogenase Proteins 0.000 description 1
- 102000001779 3-oxo-5-alpha-steroid 4-dehydrogenase Human genes 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 229940123407 Androgen receptor antagonist Drugs 0.000 description 1
- 208000032170 Congenital Abnormalities Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 229940127315 Potassium Channel Openers Drugs 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 108020004459 Small interfering RNA Proteins 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical compound IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000003936 androgen receptor antagonist Substances 0.000 description 1
- 206010068168 androgenetic alopecia Diseases 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- JXSVIVRDWWRQRT-UYDOISQJSA-N asiatic acid Chemical compound C1[C@@H](O)[C@H](O)[C@@](C)(CO)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C JXSVIVRDWWRQRT-UYDOISQJSA-N 0.000 description 1
- 229940011658 asiatic acid Drugs 0.000 description 1
- LBGFKBYMNRAMFC-PYSQTNCISA-N asiatic acid Natural products C[C@@H]1CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)C[C@@H](O)[C@H](O)[C@@](C)(CO)[C@@H]5CC[C@@]34C)[C@]2(C)[C@H]1C)C(=O)O LBGFKBYMNRAMFC-PYSQTNCISA-N 0.000 description 1
- 229960002255 azelaic acid Drugs 0.000 description 1
- 230000007698 birth defect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 238000010668 complexation reaction Methods 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- MDZKJHQSJHYOHJ-UHFFFAOYSA-N crataegolic acid Chemical class C1C(O)C(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C MDZKJHQSJHYOHJ-UHFFFAOYSA-N 0.000 description 1
- 229930182912 cyclosporin Natural products 0.000 description 1
- 229960004042 diazoxide Drugs 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 208000037765 diseases and disorders Diseases 0.000 description 1
- 230000002828 effect on organs or tissue Effects 0.000 description 1
- CLXOLTFMHAXJST-UHFFFAOYSA-N esculentic acid Natural products C12CC=C3C4CC(C)(C(O)=O)CCC4(C(O)=O)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(CO)C CLXOLTFMHAXJST-UHFFFAOYSA-N 0.000 description 1
- HQPMKSGTIOYHJT-UHFFFAOYSA-N ethane-1,2-diol;propane-1,2-diol Chemical compound OCCO.CC(O)CO HQPMKSGTIOYHJT-UHFFFAOYSA-N 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- MDZKJHQSJHYOHJ-LLICELPBSA-N maslinic acid Chemical class C1[C@@H](O)[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MDZKJHQSJHYOHJ-LLICELPBSA-N 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 229920001993 poloxamer 188 Polymers 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000004633 polyglycolic acid Substances 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229950008882 polysorbate Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 229940117382 propecia Drugs 0.000 description 1
- 229930182490 saponin Chemical class 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 235000017709 saponins Nutrition 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 229940001584 sodium metabisulfite Drugs 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000003390 teratogenic effect Effects 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 239000008181 tonicity modifier Substances 0.000 description 1
- 229940035722 triiodothyronine Drugs 0.000 description 1
- 150000003648 triterpenes Chemical class 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 229920001664 tyloxapol Polymers 0.000 description 1
- MDYZKJNTKZIUSK-UHFFFAOYSA-N tyloxapol Chemical compound O=C.C1CO1.CC(C)(C)CC(C)(C)C1=CC=C(O)C=C1 MDYZKJNTKZIUSK-UHFFFAOYSA-N 0.000 description 1
- 229960004224 tyloxapol Drugs 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US43784203P | 2003-01-03 | 2003-01-03 | |
| US60/437,842 | 2003-01-03 | ||
| PCT/US2004/000128 WO2004063331A2 (en) | 2003-01-03 | 2004-01-05 | SiRNA MEDIATED POST-TRANSRIPTIONAL GENE SILENCING OF GENES INVOLVED IN ALOPECIA |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010286475A Division JP2011120589A (ja) | 2003-01-03 | 2010-12-22 | 脱毛に関与する遺伝子の、ｓｉＲＮＡ転写後遺伝子サイレンシング |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2006524038A JP2006524038A (ja) | 2006-10-26 |
| JP2006524038A5 true JP2006524038A5 (enExample) | 2007-02-15 |
| JP4742023B2 JP4742023B2 (ja) | 2011-08-10 |
Family
ID=32713236
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006500788A Expired - Fee Related JP4742023B2 (ja) | 2003-01-03 | 2004-01-05 | 脱毛に関与する遺伝子の、ｓｉＲＮＡ転写後遺伝子サイレンシング |
| JP2010286475A Pending JP2011120589A (ja) | 2003-01-03 | 2010-12-22 | 脱毛に関与する遺伝子の、ｓｉＲＮＡ転写後遺伝子サイレンシング |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010286475A Pending JP2011120589A (ja) | 2003-01-03 | 2010-12-22 | 脱毛に関与する遺伝子の、ｓｉＲＮＡ転写後遺伝子サイレンシング |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20070141009A1 (enExample) |
| EP (2) | EP2462936A1 (enExample) |
| JP (2) | JP4742023B2 (enExample) |
| AU (1) | AU2004204068B8 (enExample) |
| CA (1) | CA2512337A1 (enExample) |
| WO (1) | WO2004063331A2 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1689864A2 (en) * | 2003-10-21 | 2006-08-16 | Dyad Pharmaceutical Corporation | Method and compositions for treating 5alpha-reductase type 1 and type 2 dependent conditions |
| WO2005045037A2 (en) * | 2003-10-23 | 2005-05-19 | Sirna Therapeutics, Inc. | RNA INTERFERENCE MEDIATED INHIBITION OF 5-ALPHA REDUCTASE AND ANDROGEN RECEPTOR GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| US20050164970A1 (en) * | 2003-12-22 | 2005-07-28 | University Of Kansas Medical Center | Method for treating prostate cancer using siRNA duplex for androgen receptor |
| US8168600B2 (en) | 2004-04-23 | 2012-05-01 | Isis Pharmaceuticals, Inc. | Compositions and methods for topical delivery of oligonucleotides |
| DE102005023170A1 (de) * | 2005-05-19 | 2006-11-23 | Curevac Gmbh | Optimierte Formulierung für mRNA |
| EP2023951A4 (en) * | 2006-05-19 | 2010-01-13 | Univ Rochester | PROSTATEEPITHEL ANDROGEN RECEPTOR FOR THE SUPPRESSION OF PROSTATE GROWTH AND TUMORINVASION |
| AR055648A1 (es) * | 2006-09-21 | 2007-08-29 | Gen Med Sa | Un oligonucleotido de rna de doble cadena una composicion farmaceutica o cosmetica que lo comprende y uso del mismo enla preparacion de un medicamento para el tratamiento de enfermedades relacionadas con el metabolismo de androgenos |
| NZ585327A (en) * | 2007-11-26 | 2012-10-26 | Santaris Pharma As | Lna antagonists targeting the androgen receptor |
| US8450290B2 (en) | 2007-11-26 | 2013-05-28 | Enzon Pharmaceuticals, Inc. | Methods for treating androgen receptor dependent disorders including cancers |
| JP5283106B2 (ja) * | 2008-03-14 | 2013-09-04 | 国立大学法人 熊本大学 | Ｃ型肝炎ウイルス阻害剤 |
| WO2013009717A1 (en) * | 2011-07-10 | 2013-01-17 | Elisabet De Los Pinos | Virion derived protein nanoparticles for delivering diagnostic or therapeutic agents for the treatment of skin-related diseases |
| EP2725103A3 (en) * | 2011-11-14 | 2016-01-06 | Silenseed Ltd | Methods and compositions for treating prostate cancer |
| US9175291B2 (en) | 2012-10-11 | 2015-11-03 | Isis Pharmaceuticals Inc. | Modulation of androgen receptor expression |
| US9655999B2 (en) | 2013-03-12 | 2017-05-23 | Carnegie Mellon University | Coated vaso-occlusive device for treatment of aneurysms |
| JP6768253B2 (ja) * | 2015-10-09 | 2020-10-14 | 井上 肇 | 対象者の男性型脱毛症に関する情報を取得する方法 |
| GB201519734D0 (en) * | 2015-11-09 | 2015-12-23 | Univ Swansea | Cancer therapy |
| KR102321426B1 (ko) * | 2017-02-21 | 2021-11-05 | 올릭스 주식회사 | 남성형 탈모 표적 유전자의 발현을 억제하는 비대칭 siRNA |
| KR102473989B1 (ko) | 2018-11-28 | 2022-12-07 | (주)바이오니아 | 안드로젠 수용체 특이적 서열을 포함하는 이중나선 올리고뉴클레오티드 구조체, 및 이를 포함하는 탈모 예방 및 발모용 조성물 |
| JP7692829B2 (ja) | 2019-07-30 | 2025-06-16 | 塩野義製薬株式会社 | Ｍｕｒｆ１を標的とする核酸医薬 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4596812A (en) | 1976-05-24 | 1986-06-24 | The Upjohn Company | Methods and solutions for treating male pattern alopecia |
| US5571817A (en) | 1984-02-27 | 1996-11-05 | Merck & Co., Inc. | Methods of treating androgenic alopecia with finasteride [17β-N-mono-substituted-carbamoyl-4-aza-5-α-androst-1-en-ones] |
| US5877160A (en) * | 1991-05-31 | 1999-03-02 | Genta Incorporated | Compositions and methods of treatment of androgen-associated baldness using antisense oligomers |
| US6733776B1 (en) * | 1992-04-02 | 2004-05-11 | Anticancer, Inc. | Method for promoting hair growth |
| AU695165B2 (en) * | 1994-07-15 | 1998-08-06 | City Of Hope | Cleavage of 5 alpha-reductase mRNA |
| US5670643A (en) | 1995-03-16 | 1997-09-23 | Glaxo Wellcome Inc. | Method for preparing finasteride |
| AU2666797A (en) * | 1996-04-15 | 1997-11-07 | Dyad Pharmaceutical Corporation | Combination therapy for androgenic alopecia with antisense oligonucleotides and minoxidil |
| US6124362A (en) | 1998-07-17 | 2000-09-26 | The Procter & Gamble Company | Method for regulating hair growth |
| US20080039414A1 (en) * | 2002-02-20 | 2008-02-14 | Sima Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
| CN100523215C (zh) * | 2000-12-01 | 2009-08-05 | 马普科技促进协会 | 介导rna干涉的小rna分子 |
| JP4173667B2 (ja) * | 2001-02-28 | 2008-10-29 | 北海道三井化学株式会社 | アンドロゲン受容体作用阻害剤 |
| US20050159376A1 (en) * | 2002-02-20 | 2005-07-21 | Slrna Therapeutics, Inc. | RNA interference mediated inhibition 5-alpha reductase and androgen receptor gene expression using short interfering nucleic acid (siNA) |
| US20050170371A1 (en) * | 2001-05-18 | 2005-08-04 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of 5-alpha reductase and androgen receptor gene expression using short interfering nucleic acid (siNA) |
| JP4869498B2 (ja) * | 2001-05-31 | 2012-02-08 | 丸善製薬株式会社 | 抗男性ホルモン剤、及び養毛化粧料、皮脂分泌抑制剤並びに前立腺肥大抑制剤 |
| EP1432724A4 (en) * | 2002-02-20 | 2006-02-01 | Sirna Therapeutics Inc | RNA inhibition mediated inhibition of MAP KINASE GENES |
| FR2840217B1 (fr) * | 2002-06-03 | 2005-06-24 | Oreal | Compositions cosmetiques comprenant au moins un oligonucleotide d'arn double brin (dsrna)et leurs utilisations |
| TW200413725A (en) * | 2002-09-30 | 2004-08-01 | Oncotherapy Science Inc | Method for diagnosing non-small cell lung cancers |
| US20060024692A1 (en) * | 2002-09-30 | 2006-02-02 | Oncotherapy Science, Inc. | Method for diagnosing non-small cell lung cancers |
| EP1689864A2 (en) * | 2003-10-21 | 2006-08-16 | Dyad Pharmaceutical Corporation | Method and compositions for treating 5alpha-reductase type 1 and type 2 dependent conditions |
| US20050164970A1 (en) * | 2003-12-22 | 2005-07-28 | University Of Kansas Medical Center | Method for treating prostate cancer using siRNA duplex for androgen receptor |
-
2004
- 2004-01-05 WO PCT/US2004/000128 patent/WO2004063331A2/en not_active Ceased
- 2004-01-05 EP EP11194122A patent/EP2462936A1/en not_active Withdrawn
- 2004-01-05 JP JP2006500788A patent/JP4742023B2/ja not_active Expired - Fee Related
- 2004-01-05 CA CA002512337A patent/CA2512337A1/en not_active Abandoned
- 2004-01-05 US US10/544,320 patent/US20070141009A1/en not_active Abandoned
- 2004-01-05 AU AU2004204068A patent/AU2004204068B8/en not_active Ceased
- 2004-01-05 EP EP04700221A patent/EP1590430A4/en not_active Withdrawn
-
2010
- 2010-12-22 JP JP2010286475A patent/JP2011120589A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA1262335A (en) | Hair growth modification | |
| CN111936149B (zh) | 用于预防或治疗毛发脱落或者促进毛发生长的药物组合物或化妆品组合物 | |
| PL200835B1 (pl) | Lotion do włosów | |
| JP2020513211A (ja) | 皮膚および毛髪の治療のためのミトコンドリア組成物および方法 | |
| JP2011120589A (ja) | 脱毛に関与する遺伝子の、ｓｉＲＮＡ転写後遺伝子サイレンシング | |
| JP2022506944A (ja) | ５－α－レダクターゼ阻害剤の局所製剤及びそれらの使用 | |
| EP0777458B1 (en) | Control of hair growth | |
| ES2757816T3 (es) | Utilización del 2,3-dihidroxipropil dodecanoato para el tratamiento de la seborrea | |
| US20080207545A1 (en) | Methods and Compositions for Treating 5Alpha-Reductase Type 1 and Type 2 Dependent Conditions | |
| US20100311813A1 (en) | Antiandrogen oligonucleotides usable for the treatment of dermatological androgen-related disorders relating to androgen metabolism, their pharmaceutical compositions, their uses and treatment method | |
| Ipek et al. | Relationship between neutrophil-to-lymphocyte ratio and left ventricular free wall rupture in acute myocardial infarction | |
| TW590771B (en) | Serine protease and topical retinoid compositions useful for treatment of acne vulgaris and production of anti-aging effects | |
| US6204258B1 (en) | Method of treating alopecia | |
| EP2719762A1 (de) | Tyrosinaseinhibitoren zur Depigmentierung oder Haarentfernung | |
| TWI758437B (zh) | 水田芥水性萃取物與金蓮花水性萃取物及三磷酸腺苷（ａｔｐ）之組合於治療禿髮之技術 | |
| John et al. | Emerging oral treatments: oral minoxidil for androgenetic alopecia | |
| US8580236B2 (en) | Hair sustaining formulation | |
| JP2022530077A (ja) | Ｈａｐｌｎ１を含む脱毛の予防用または治療用の組成物 | |
| KR102530037B1 (ko) | 타베르소닌을 포함하는 탈모방지 및 발모 촉진용 조성물 | |
| US20260083789A1 (en) | Formulation for stimulating hair growth and improving quality and method of preparation of the same | |
| JP2024541722A (ja) | 乾癬により誘発されたかゆみの処置における使用のためのアンチセンスオリゴヌクレオチド及び前記オリゴヌクレオチドを含むリン脂質小胞 | |
| KR102611504B1 (ko) | 키레놀을 포함하는 탈모방지 및 발모촉진용 조성물 | |
| HK40112490A (en) | Antisense oligonucleotide for use in the treatment of psoriasis-induced itching and phospholipid vesicle comprising said oligonucleotide | |
| EP4082518A1 (en) | Fatty acid compositions for the treatment and prevention of hair loss and alopecia | |
| CN102458351A (zh) | 皮肤水分透过功能异常的预防或治疗剂 |